These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26200267)

  • 1. Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
    Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
    J Thorac Oncol; 2015 Aug; 10(8):1142-7. PubMed ID: 26200267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable treatment response of bevacizumab-combined chemotherapy for advanced or recurrent invasive mucinous adenocarcinoma of the lung: A retrospective observational study.
    Fujimoto K; Sekine A; Hagiwara E; Asaoka M; Ikeda S; Baba T; Komatsu S; Ogura T
    Respir Investig; 2024 May; 62(3):360-364. PubMed ID: 38428089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020.
    García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Ruiz M; Espín J; Expósito-Hernández J
    Am J Clin Oncol; 2023 Oct; 46(10):433-438. PubMed ID: 37522643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma.
    Dansby J; More A; Zeineddine M; Yousef A; Bent A; Dayyani F; Wolff R; Overman M; Shen JP
    Oncologist; 2023 Dec; 28(12):e1303-e1305. PubMed ID: 37738316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane-based Chemotherapy is Effective in Metastatic Appendiceal Adenocarcinoma.
    Dansby J; More A; Zeineddine M; Yousef A; Bent A; Dayyani F; Wolff R; Overman M; Shen JP
    medRxiv; 2023 Jul; ():. PubMed ID: 37502847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases.
    Kim YH; Mishima M
    J Thorac Oncol; 2015 Aug; 10(8):e76. PubMed ID: 26200284
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer.
    Ichihara E; Hotta K; Kiura K
    J Thorac Oncol; 2015 Aug; 10(8):e79. PubMed ID: 26200288
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer.
    Zhang X
    J Thorac Oncol; 2015 Aug; 10(8):e78-9. PubMed ID: 26200287
    [No Abstract]   [Full Text] [Related]  

  • 9. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study.
    Yoshida K; Yamada Y
    Transl Lung Cancer Res; 2015 Jun; 4(3):217-9. PubMed ID: 26207207
    [No Abstract]   [Full Text] [Related]  

  • 10. Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor.
    Hermanson TT; Hrushesky WJ; Knopf KB; Bennett CL
    J Oncol Pract; 2015 Sep; 11(5):363-4. PubMed ID: 26243648
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
    Chen J; Lu Y; Zheng Y
    Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
    Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
    Cascone T; Heymach JV
    Clin Cancer Res; 2015 Dec; 21(23):5188-90. PubMed ID: 26232370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
    Aghajanian C; Goff B; Nycum LR; Wang YV; Husain A; Blank SV
    Gynecol Oncol; 2015 Oct; 139(1):10-6. PubMed ID: 26271155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
    Modest DP; Stintzing S; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Möhler M; Jung A; Kirchner T; Heinemann V
    J Clin Oncol; 2015 Nov; 33(32):3718-26. PubMed ID: 26261259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
    Syrios J; Nintos G; Georgoulias V
    Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
    Bronte G; Passiglia F; Galvano A; Russo A
    Expert Opin Biol Ther; 2016; 16(1):1-5. PubMed ID: 26235195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of rapid infusion of the initial dose of bevacizumab in patients with cancer.
    Makris G; Kantzioura A; Beredima M; Karampola M; Emmanouilides C
    J BUON; 2015; 20(3):923-7. PubMed ID: 26214648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
    Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
    J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.